EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 411 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer May 21, 2024 News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and... June 20, 2020 Exposure to Antibiotics, Specifically Fluoroquinolones, Before Treatment with Immune Checkpoint Inhibitor... March 6, 2023 FDA Grants Accelerated Approval to Daratumumab Plus Hyaluronidase for Newly Diagnosed... January 22, 2021 Load more HOT NEWS Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,... Can I Have a Non-Violent Relationship with Cancer (Part 2) Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’...
